Background. Look-alike, sound-alike (LASA) drug names are a cause of medication errors with
Introduction
Medication errors occur at all stages in medication use including ordering, transcribing, dispensing, and administration. [1] [2] [3] A look-alike, sound-alike (LASA) error is the erroneous prescription, dispensing or delivery of a drug because the name of the drug is similar in appearance to or sounds like another drug. [4, 5] In 1973, Benjamin Teplitsky published the first list of look-alike or sound-alike drug (LASA) names. [6] The FDA has published lists of LASA generic and brand names [7, 8] and newly FDA-identified LASA errors are subject to safety communications. [9, 10] Since 2008, the Institute for Safe Medication Practices has also regularly published a list of LASA drug name pairs. [11] The United States (US) Pharmacopeia has identified 1,470 drugs involved in LASA errors. [12] Systematic quantitative estimates of LASA incidents are lacking. LASA errors are often identified through spontaneous reporting, retrospective chart review, and computer triggers. [13] Prior research assessed LASA errors in a specific therapeutic area, [14, 15] patient population [16] [17] [18] [19] or healthcare setting. [16, [20] [21] [22] [23] LASA errors are reported cause of medication errors threatening patient safety. [24] [25] [26] [27] Errors due to LASA drugs may cause patients' harm and death. [16, 19, 28] It has been estimated that 1.4% of LASA drug errors result in adverse and harmful patient outcomes. [12] Additionally, LASA errors may also result in substantial healthcare costs. [27] To our knowledge, no studies have assessed the potential to reduce LASA errors by using the U.S. Food and Drug Administration (FDA) approved drug indication to differentiate LASA drug pairs. Thus, the aim of this study was to assess to which extent the use of the generic drug name, therapeutic class, health problem, and FDA-approved indications may help differentiating LASA drug pairs.
Methods
We collected information about LASA drug pairs reported by the FDA to have look-alike sound-alike similarities available at the FDA Office of Generic Drugs Name Project [7] the Drug Products Associated with Medication Errors website [8] and two FDA safety communications. [9, 10] The Anatomical Therapeutic Chemical (ATC) classification system therapeutic class for LASA drugs were extracted from the WHO Collaborating Centre for Drug Statistics Methodology. [29] A complete list of indications for each drug was extracted from the latest available version of the FDA approved labels. The FDA label information was collected from the Labels@FDA and Drugs@FDA online databases. [30, 31] The database Dailymed was searched as needed for labels not available at the FDA websites or for labels of drugs discontinued from the US market. [32] The indication information was extracted from the indications and usage section of the FDA label. This section provides a concise statement about the use of the drug for "the treatment, prevention, mitigation, cure, or diagnosis of a recognized disease or condition, or of a manifestation of a recognized disease or condition, or for the relief of symptoms associated with a recognized disease or condition." [33] The indications and usage section may also include major limitations of use (e.g., use in particular subsets of the population, line of therapy status).
The health problem information was extracted from the FDA-labeled indication. The health problem was defined as the disease, condition, manifestation or symptom described in the indications and usage section of the label. The general concept of the health problem as defined in the FDA-approved label was used for the analysis. We also examined the most detailed concept of the health problem contained in the FDA-approved label. For example, cyclosporine is indicated for "the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate." In this case, we considered "arthritis" to be the general health problem, and "treatment of patients with severe active, rheumatoid arthritis" the most detailed health problem concept. Table 1 provides an example of a LASA drug pair (i.e., daunorubicin citrate liposomal and doxorubicin liposomal) and illustrates how a side-by-side comparison of the drug characteristics may help differentiating two LASA drugs that have similar generic names.
Dunorubicin and doxorubicin cannot be differentiated using their therapeutic class or the general health problem. The detailed health problem may help in part to differentiate these two subtly different drugs and indications because while "AIDS-related Kaposi's sarcoma" is a parent concept of "Advanced HIV-associated Kaposi's sarcoma" the FDA-approved indication differs in terms of the line of therapy and specifies that daunorubicin is the first line therapy for patients with advanced HIV-associated Kaposi's sarcoma. We collected the indications for all routes, dosage forms, and strengths approved for the each drug to account for possible changes in indications depending on those drug characteristics.
To assess differences among LASA drug pairs, we compared each of the following drug characteristics: generic name, therapeutic class, health problem, and FDA-approved indication.
We also assessed differences among LASA drug pairs including all of the above characteristics as a bundle.
We assessed differences in the FDA-approved indications for each LASA drug pair to account for drugs that have multiple indications with different health problems or therapeutic class. We also assessed if the indications of each LASA drug pair were the same or different.
Data were descriptively assessed following a structured and standardized approach. A standardized data abstraction form, using a spreadsheet template in MS Excel, and a checklist were developed and utilized by the authors to assess differences in LASA drug pairs. The data abstraction form included the generic name, general and detailed health problems, and indications described in the FDA-approved drug label and the therapeutic subclass from the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) Classification System. [29] The data abstraction form also included characteristics of assessed drugs. Two authors abstracted information from the FDA approved-label independently. The results from the data abstraction were compared after completing the review of the labels. Discrepancies between authors were resolved by a third author retrieving the information from the drug label.
Descriptive analyses were performed using MS Excel 2013.
Results
As of July 30, 2016, we collected information for 33 LASA drug pairs reported by the FDA. LASA drug pairs included 21 (31.8%) brand names and 45 (68.2%) generic names ( Table   2 ). The LASA drug names included a total of 60 different active ingredients. An active ingredient may be included in more than one LASA drug pair; 6 single active ingredients (i.e., and cardiovascular system (9, 13.6%). There were 4 drugs (i.e., medroxyprogesterone acetate, methylprednisolone acetate, prednisolone, and prednisone) with codes in 3 or more ATC anatomic classes.
LASA drug pairs included a total of 432 FDA-approved indications with a median of 2 indications per drug (range 1-77) ( Table 3) . Of the total 432 FDA-approved indications, 152 (35.2%) were the same indication for both drugs in the pair and 280 (64.8%) were different.
There were 20 drugs (30.3% of all LASA drugs) with only 1 approved indication.
Two LASA drugs (acetohexamide and sulfisoxazole) were discontinued from the U.S. In addition, using the most detailed health problem alone, defined in the FDA-approved drug label, we were able to differentiate the same number of LASA drug pairs as using the drug indication (26; 78.8%). Using all of the assessed drug characteristics (i.e., generic name, therapeutic class, general and detailed health problem, and indication) as a bundle we managed to differentiate the same number of LASA drug pairs and FDA-approved indications as using the FDA-approved indication alone.
Likewise, using the generic name, therapeutic class and general health problem we that had a total of 152 (35.2%) FDA-approved indications that we could not differentiate using the drug characteristics assessed in this study (i.e. generic name, therapeutic class, general and detailed health problem, and indication).
Discussion
The indication, or purpose of a drug, is an essential component of the information needed for appropriate drug selection, prescribing, and utilization. The drug indication is the link between the patient's health problem and a specific drug being prescribed to a patient. This study provides evidence that including the FDA-approved drug indication in the prescription may be used to differentiate two-thirds of the LASA drugs pairs and thus, it has the potential to identify and prevent LASA errors and harm.
LASA drug errors are a cause of medication errors in the US and may result in significant patients' harm and health care costs. Evaluating the true incidence of LASA errors and its related outcomes remains a challenge due to poor reporting, differences in definitions of medication errors, fear of litigation, inability to determine causality, and cost.
Several strategies have been proposed to reduce LASA medication errors including the use of Tall Man lettering, [22, 34] computerized provider order medication entry with (or without) electronic prescription transmission, medication reconciliation processes, barcode systems, and package changes. [1, 35, 36] Additional proposed measures include enhancing labeling for injectable medications that have similar appearing packaging, including security symbols, putting special labels on packaging of high-risk drugs, and revising processes for selecting, maintaining and updating the list of LASA drugs. [26] The FDA has published guidance intended to assist the industry in the selection of drug names for new medications as well as in the submission of safety aspects related with a proposed proprietary name to reduce medication errors. [37] Better pre-approval testing of drug names to reduce the number of confusing LASA drug pairs has also been proposed. There is growing consensus that including the indication in the prescription is desirable and feasible given emerging capabilities of electronic prescribing. [45] We have shown here one safety benefit that is both potentially powerful but also imperfect, since it could help differentiate most, but not all LASA. Some EHR and electronic prescribing systems are already capable of linking the drug with the health problem list, the indication and other drug characteristics but engineering the workflow to make this easier and accurate remains a current work in progress. [46] The use of the detailed health problem and the FDA-approved indication may be too complex to differentiate LASA drug pairs without the use of electronic decision support systems. Health systems without fully integrated electronic decision support systems could still benefit from the use of the generic name, the therapeutic class and the general health problem to differentiate drug LASA pairs. For these clearly differentiated pairs inclusion of the indication would help pharmacists, other clinicians and patients more easily recognize and intercept LASA prescribing, dispensing and administration errors.
The increasing use of electronic prescribing may reduce LASA drug errors, but might also potentially contribute to LASA drug errors due to picklist errors (juxtaposition picking errors from drug dropdown lists). The use of the indication may also potentially reduce this type of LASA errors.
This study examined LASA drug pairs identified by the FDA and did not include indications not approved by the FDA (i.e. off-label indications). We elected to confine the scope of our study to approved labeled indications because we felt this would be a conservative approach for obtaining a valid set of established indications to cross reference with prescription indications. There is no inherent reason such a system could not be used for both labeled and off-labeled indications. [45] An important question for the present study is how this might impact on our conclusion that FDA approved indications could help flag LASA medication errors. We believe there is no fundamental reason given drugs general pharmacologic properties (e.g.
antibiotics are generally not used off-label for hypertension) although we cannot exclude the possibility that in rare cases a broadened medication list could permit a lowered bar that could as a result, overlook a LASA drug pair. We could also envision a related positive byproduct that would potentially flag off-label uses, although we would want to be cautious about added alert/fatigue burden on prescribers.
Concerns regarding the additional prescriber's time and effort needed to specify the indication in the prescription and patient's privacy have not been assessed in this study. However there is growing capability to automate such linkages and thereby facilitate incorporating the indication into the drug prescription and prescribing workflow. The Health Insurance Portability and Accountability Act of 1996 and other current patient confidentiality and privacy regulations do not preclude against the inclusion of the indication in the prescription. However, a patient can request not to include the indication in the prescription. More research is needed to empirically determine to which extent including the indication and other drug characteristics in the prescription prevent LASA drug errors in clinical practice.
Conclusions
Using the drug indication we were able to differentiate over three-fourths of assessed FDA identified LASA drug pairs. Including the FDA-approved indication in the drug prescription helps to differentiate LASA drug pairs and thus, may improve medication safety.
